초록 ▼

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (SEQ ID NO:50).

대표청구항 ▼

1. A method of treating a skin disorder by enhancing delivery of an immunosuppressive conjugate into and across one or more layers of the skin of an animal, the method comprising,contacting the skin of the animal with an immunosuppressive conjugate formed from an ascomycin and a delivery-enhancing t

1. A method of treating a skin disorder by enhancing delivery of an immunosuppressive conjugate into and across one or more layers of the skin of an animal, the method comprising,contacting the skin of the animal with an immunosuppressive conjugate formed from an ascomycin and a delivery-enhancing transporter,wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across skin compared to delivery of the ascomycin in the absence of the delivery-enhancing transporter. 2. The method of claim 1, wherein the skin disorder is selected from the group consisting of psoriasis, eczema, atopic dermatitis, contact dermatitis, allergic dermatitis, and alopecia areata. 3. The method of claim 1, wherein the ascomycin is selected from the group consisting of FK506 and rapamycin. 4. The method of claim 1, wherein the delivery-enhancing transporter comprises a non-peptide backbone. 5. The method of claim 1, wherein the delivery-enhancing transporter comprises from 5 to 25 guanidino or amidino moieties. 6. The method of claim 5, wherein the delivery-enhancing transporter comprises between 7 and 15 guanidino moieties. 7. The method of claim 1, wherein the delivery-enhancing transporter comprises at least 6 contiguous guanidino and/or amidino moieties. 8. The method of claim 1, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or analogs thereof. 9. The method of claim 1, wherein the delivery-enhancing transporter comprises 5 to 25 arginine residues or analogs thereof. 10. The method of claim 9, wherein the delivery-enhancing transporter comprises 8 arginine residues. 11. The method of claim 9, wherein at least one arginine is a D-arginine. 12. The method of claim 11, wherein all of the arginines are D-arginines. 13. The method of claim 8, wherein at least 70 percent of the amino acids that comprise the delivery-enhancing transporter are arginines or arginine analogs. 14. The method of claim 8, wherein the delivery-enhancing transporter comprises at least 5 contiguous arginines or arginine analogs. 15. The method of claim 1, wherein delivery of the compound into and across the skin is at least two-fold greater than that of the compound conjugated to a basic HIV tat peptide consisting of residues 49-57. 16. The method of claim 1, wherein the ascomycin is attached to the delivery enhancing transporter by a linker. 17. A method of treating a fungal infection of the skin by enhancing delivery of an anti-fungal conjugate into and across one or more layers of the skin of an animal, the method comprising,contacting the skin of the animal with the conjugate;wherein the conjugate comprises an anti-fungal agent and a delivery-enhancing transporter, andwherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across skin compared to delivery of the anti-fungal agent in the absence of the delivery-enhancing transporter. 18. The method of claim 17, wherein the fungal infection is selected from the group consisting of tinea corporis, tinea pedis, onychomycosis, candidiasis, and tinea versicolor. 19. The method of claim 17, wherein the delivery-enhancing transporter comprises a non-peptide backbone. 20. The method of claim 17, wherein the delivery-enhancing transporter comprises from 5 to 25 guanidino or amidino moieties. 21. The method of claim 20, wherein the delivery-enhancing transporter comprises between 7 and 15 guanidino moieties. 22. The method of claim 17, wherein the delivery-enhancing transporter comprises at least 6 contiguous guanidino and/or amidino moieties. 23. The method of claim 17, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or analogs thereof. 24. The method of claim 17, wherein the deliv ery-enhancing transporter comprises 5 to 25 arginine residues or analogs thereof. 25. The method of claim 24, wherein the delivery-enhancing transporter comprises 8 arginine residues. 26. The method of claim 24, wherein at least one arginine is a D-arginine. 27. The method of claim 26, wherein all of the arginines are D-arginines. 28. The method of claim 23, wherein at least 70 percent of the amino acids that comprise the delivery-enhancing transporter are arginines or arginine analogs. 29. The method of claim 17, wherein the delivery-enhancing transporter comprises at least 5 contiguous arginines or arginine analogs. 30. The method of claim 17, wherein delivery of the compound into and across the skin is at least two-fold greater than that of the compound conjugated to a basic HIV tat peptide consisting of residues 49-57. 31. The method of claim 17, wherein the antifungal agent is attached to the delivery enhancing transporter by a linker.